Fernando P Polack1, Ruth A Karron. 1. Department of Intenational Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Abstract
BACKGROUND: Respiratory syncytial virus (RSV) is the leading cause of viral lower respiratory tract illness in infants and children and is an important cause of lower respiratory tract illness in other populations. Despite decades of research there are currently no licensed vaccines for prevention of RSV disease. METHODS: A review of the obstacles to RSV vaccine development; current live, attenuated and subunit RSV vaccines in clinical development; and the potential for developing additional vaccine candidates based on recombinant technology. RESULTS: A number of biologically derived live attenuated RSV vaccines were evaluated in Phase I clinical trials in adults and children, and one vaccine (cpts 248/404) was evaluated in infants as young as 1 month of age. These vaccines displayed a spectrum of attenuation, with cpts 248/955 being the least attenuated and cpts 248/404 being the most attenuated candidate vaccine. None of these was sufficiently attenuated for young infants. The ability to generate recombinant RSV vaccines has led to the development of large numbers of candidate vaccines containing combinations of known attenuating point mutations and deletions of nonessential genes. Clinical evaluation of many of these candidates is in progress. Three types of RSV subunit vaccines have recently been evaluated in clinical trials: purified F glycoprotein vaccines (PFP-1, PFP-2 and PFP-3), BBG2Na and copurified F, G and M proteins. Additional studies of the F/G/M protein vaccine are being conducted. CONCLUSIONS: During the past 10 years, considerable progress has been made in RSV vaccine development. It is likely that different RSV vaccines will be needed for the various populations at risk.
BACKGROUND:Respiratory syncytial virus (RSV) is the leading cause of viral lower respiratory tract illness in infants and children and is an important cause of lower respiratory tract illness in other populations. Despite decades of research there are currently no licensed vaccines for prevention of RSV disease. METHODS: A review of the obstacles to RSV vaccine development; current live, attenuated and subunit RSV vaccines in clinical development; and the potential for developing additional vaccine candidates based on recombinant technology. RESULTS: A number of biologically derived live attenuated RSV vaccines were evaluated in Phase I clinical trials in adults and children, and one vaccine (cpts 248/404) was evaluated in infants as young as 1 month of age. These vaccines displayed a spectrum of attenuation, with cpts 248/955 being the least attenuated and cpts 248/404 being the most attenuated candidate vaccine. None of these was sufficiently attenuated for young infants. The ability to generate recombinant RSV vaccines has led to the development of large numbers of candidate vaccines containing combinations of known attenuating point mutations and deletions of nonessential genes. Clinical evaluation of many of these candidates is in progress. Three types of RSV subunit vaccines have recently been evaluated in clinical trials: purified F glycoprotein vaccines (PFP-1, PFP-2 and PFP-3), BBG2Na and copurified F, G and M proteins. Additional studies of the F/G/M protein vaccine are being conducted. CONCLUSIONS: During the past 10 years, considerable progress has been made in RSV vaccine development. It is likely that different RSV vaccines will be needed for the various populations at risk.
Authors: Luis Martinez-Sobrido; Negin Gitiban; Ana Fernandez-Sesma; Jerome Cros; Sara E Mertz; Nancy A Jewell; Sue Hammond; Emilio Flano; Russell K Durbin; Adolfo García-Sastre; Joan E Durbin Journal: J Virol Date: 2006-02 Impact factor: 5.103
Authors: Amy S Espeseth; Pedro J Cejas; Michael P Citron; Dai Wang; Daniel J DiStefano; Cheryl Callahan; Gregory O' Donnell; Jennifer D Galli; Ryan Swoyer; Sinoeun Touch; Zhiyun Wen; Joseph Antonello; Lan Zhang; Jessica A Flynn; Kara S Cox; Daniel C Freed; Kalpit A Vora; Kapil Bahl; Andrew H Latham; Jeffrey S Smith; Marian E Gindy; Giuseppe Ciaramella; Daria Hazuda; Christine A Shaw; Andrew J Bett Journal: NPJ Vaccines Date: 2020-02-14 Impact factor: 7.344
Authors: John A Ellis; Brittany V Martin; Cheryl Waldner; Kimberly D Dyer; Joseph B Domachowske; Helene F Rosenberg Journal: Vaccine Date: 2006-10-12 Impact factor: 3.641
Authors: Elizabeth J McFarland; Ruth A Karron; Petronella Muresan; Coleen K Cunningham; Megan E Valentine; Charlotte Perlowski; Bhagvanji Thumar; Devasena Gnanashanmugam; George K Siberry; Elizabeth Schappell; Emily Barr; Vivian Rexroad; Ram Yogev; Stephen A Spector; Mariam Aziz; Nehali Patel; Mikhaela Cielo; Cindy Luongo; Peter L Collins; Ursula J Buchholz Journal: J Infect Dis Date: 2018-04-11 Impact factor: 5.226
Authors: Youngjoo Choi; Caleb S Mason; Les P Jones; Jackelyn Crabtree; Patricia A Jorquera; Ralph A Tripp Journal: Viral Immunol Date: 2012-05-02 Impact factor: 2.257
Authors: U Schauer; S Hoffjan; T Rothoeft; H Bartz; S Konig; E Fuchs; J Bittscheidt; A Kochling; V Stephan Journal: Clin Exp Immunol Date: 2004-10 Impact factor: 4.330
Authors: D James Nokes; Emelda A Okiro; Mwanajuma Ngama; Rachel Ochola; Lisa J White; Paul D Scott; Michael English; Patricia A Cane; Graham F Medley Journal: Clin Infect Dis Date: 2008-01-01 Impact factor: 9.079